AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28756943 — intervention group
Group type: EXPERIMENTAL
Intervention: Holter analysis (heart rate and heart rate variability)
Number of subjects: 48
Study 28756943 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported stress
Number of subjects: 48
Study 28756943 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary cortisol
Number of subjects: 48
Study 27086023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with 24-gray EMB and ongoing pro re nata (PRN) ranibizumab (n = 224)
Number of subjects: 363
Study 27086023 — intervention group
Group type: COMPARATOR
Intervention: Ongoing PRN ranibizumab monotherapy (n = 119)
Number of subjects: 363
Study 27086023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy with 24-gray EMB and ongoing PRN ranibizumab (n = 224)
Number of subjects: 363
Study 25084784 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard polyurethane catheter securement device
Number of subjects: 220
Study 25084784 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue adhesive catheter securement device
Number of subjects: 220
Study 25084784 — intervention group
Group type: EXPERIMENTAL
Intervention: Bordered polyurethane catheter securement device
Number of subjects: 220
Study 25084784 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutureless securement device
Number of subjects: 220
Study 25084784 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial design with 388 patients/arm
Number of subjects: 220
Study 23227680 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian cosmetology treatment (including acupuncture at specific body acupoints and local needling therapy)
Number of subjects: 300
Study 23227680 — intervention group
Group type: COMPARATOR
Intervention: Western medication (oral administration of Vitamin C and E for 3 months)
Number of subjects: 300
Study 23227680 — intervention group
Group type: EXPERIMENTAL
Intervention: Meridian cosmetology treatment
Number of subjects: 300
Study 20978028 — intervention group
Group type: EXPERIMENTAL
Intervention: QVA149 (indacaterol/NVA237) 300/50 μg
Number of subjects: 154
Study 20978028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 154
Study 20978028 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 300 μg
Number of subjects: 154
Study 20978028 — intervention group
Group type: COMPARATOR
Intervention: Indacaterol 600 μg
Number of subjects: 154
Study 18617080 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (20 weekly group sessions encouraging calorie restriction, moderate-intensity physical activity, and the DASH dietary pattern)
Number of subjects: 1685
Study 18617080 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral measures (diet records and physical activity)
Number of subjects: 1685
Study 18617080 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American men
Number of subjects: 1685
Study 18617080 — intervention group
Group type: EXPERIMENTAL
Intervention: African-American women
Number of subjects: 1685
Study 18617080 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-African-American men
Number of subjects: 1685
Study 18617080 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-African-American women
Number of subjects: 1685
Study 16037157 — intervention group
Group type: EXPERIMENTAL
Intervention: Narcotrend monitoring
Number of subjects: 120
Study 16037157 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS monitoring
Number of subjects: 120
Study 16037157 — intervention group
Group type: COMPARATOR
Intervention: Standard practice
Number of subjects: 120
Study 12783044 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX; N = 12)
Number of subjects: 24
Study 12783044 — intervention group
Group type: COMPARATOR
Intervention: Control (CT; N = 12)
Number of subjects: 24
Study 10322585 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf-stretching exercises (4 static stretches, each lasting 30 seconds)
Number of subjects: 20
Study 10322585 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no calf-stretching exercises)
Number of subjects: 20
Study 8726550 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief standardized educational intervention
Number of subjects: 0
Study 8726550 — intervention group
Group type: COMPARATOR
Intervention: Sexual Beliefs and Information Questionnaire (SBIQ)
Number of subjects: 0
Study 1655219 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus involved-field radiation therapy (24 patients)
Number of subjects: 180
Study 1655219 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (24 patients)
Number of subjects: 180
Study 7052009 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 0
Study 7052009 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline hydrochloride
Number of subjects: 0
Study 7052009 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30725289 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic steering of capsule endoscopy
Number of subjects: 227
Study 30725289 — intervention group
Group type: COMPARATOR
Intervention: Standard protocol (historical control)
Number of subjects: 227
Study 28879645 — intervention group
Group type: EXPERIMENTAL
Intervention: SB2 (infliximab biosimilar)
Number of subjects: 30
Study 28879645 — intervention group
Group type: EXPERIMENTAL
Intervention: EU-sourced Remicade (EU-IFX)
Number of subjects: 30
Study 28879645 — intervention group
Group type: EXPERIMENTAL
Intervention: US-sourced Remicade (US-IFX)
Number of subjects: 30
Study 28879645 — intervention group
Group type: COMPARATOR
Intervention: Subjects with ADAs vs. those without ADAs
Number of subjects: 30
Study 28879645 — intervention group
Group type: COMPARATOR
Intervention: Serum infliximab at 8 weeks
Number of subjects: 30
Study 25168346 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons shown radiographs and patient information
Number of subjects: 238
Study 25168346 — intervention group
Group type: COMPARATOR
Intervention: Surgeons shown radiographs alone
Number of subjects: 238
Study 25168346 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient information (age, mechanism of injury)
Number of subjects: 238
Study 25168346 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons with patient information
Number of subjects: 238
Study 25168346 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeons with and without patient information
Number of subjects: 238
Study 24530144 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 120
Study 24530144 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 22353006 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Based Family Intervention (HBFI)
Number of subjects: 43
Study 22353006 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 43
Study 22353006 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HBFI and ETAU)
Number of subjects: 43
Study 19214661 — intervention group
Group type: EXPERIMENTAL
Intervention: Prokinetic agent (mosapride 15 mg, orally three times daily) for 4 weeks
Number of subjects: 26
Study 19214661 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (11 matched individuals)
Number of subjects: 26
Study 17425617 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid backboard
Number of subjects: 23
Study 17425617 — intervention group
Group type: COMPARATOR
Intervention: No backboard
Number of subjects: 23
Study 15325893 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% C31G
Number of subjects: 0
Study 15325893 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% C31G
Number of subjects: 0
Study 15325893 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.7% C31G
Number of subjects: 0
Study 15325893 — intervention group
Group type: COMPARATOR
Intervention: Extra Strength Gynol II (N-9)
Number of subjects: 0
Study 15325893 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% C31G vs. N-9
Number of subjects: 0
Study 15325893 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% C31G vs. N-9
Number of subjects: 0
Study 15325893 — intervention group
Group type: EXPERIMENTAL
Intervention: Leakage
Number of subjects: 0
Study 15325893 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptability
Number of subjects: 0
Study 15325893 — intervention group
Group type: EXPERIMENTAL
Intervention: C31G plasma levels
Number of subjects: 0
Study 11445849 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur (FT) alone or FT plus low doses of cisplatin
Number of subjects: 71
Study 11360524 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP) 1000 micrograms daily for 6 weeks
Number of subjects: 61
Study 11360524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 8198943 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady exercise for 8 min
Number of subjects: 8
Study 8198943 — intervention group
Group type: EXPERIMENTAL
Intervention: FEV1 measurements
Number of subjects: 8
Study 8198943 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus FEV1 measurements
Number of subjects: 8
Study 8198943 — intervention group
Group type: COMPARATOR
Intervention: Control (no manoeuvre)
Number of subjects: 8
Study 8198943 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvres
Number of subjects: 8
Study 8198943 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperventilation for 3 min
Number of subjects: 8
Study 3045746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily, 3 tablets during the day and 2 tablets at night)
Number of subjects: 37
Study 3045746 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1 g daily)
Number of subjects: 37
Study 3045746 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine-Placebo
Number of subjects: 37
Study 30747267 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BRJ) supplementation (8.4 mmol NO3‐ day‐ 1)
Number of subjects: 13
Study 30747267 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) (0.01 mmol NO3‐ day‐ 1)
Number of subjects: 13
Study 28259304 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive alcohol ingestion
Number of subjects: 199
Study 26394270 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate 40 mg/mL three times weekly subcutaneous injection (GA40)
Number of subjects: 1404
Study 26394270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1404
Study 23385649 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Slow Breathing (SLOWB)
Number of subjects: 10
Study 23385649 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term Slow Breathing (SLOWB)
Number of subjects: 10
Study 23385649 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched hypertensive controls)
Number of subjects: 10
Study 21559038 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g/d BSP (n=21)
Number of subjects: 81
Study 21559038 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g/d BSP (n=22)
Number of subjects: 81
Study 21559038 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 81
Study 17964616 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein preload (300 mL, 1 MJ)
Number of subjects: 20
Study 17964616 — intervention group
Group type: COMPARATOR
Intervention: Control preload (low protein)
Number of subjects: 20
Study 17964616 — intervention group
Group type: EXPERIMENTAL
Intervention: GMP preload (GMP isolate)
Number of subjects: 20
Study 17964616 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey (‐)GMP preload (whey protein without GMP)
Number of subjects: 20
Study 16767021 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation with limited tidal volume size and respiratory rate
Number of subjects: 0
Study 16767021 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of positive end expiratory pressure
Number of subjects: 0
Study 16767021 — intervention group
Group type: EXPERIMENTAL
Intervention: Application of helium‐oxygen mixtures
Number of subjects: 0
Study 16767021 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific inspiratory and expiratory ratios
Number of subjects: 0
Study 14668455 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-drug regimen containing efavirenz combined with zidovudine and lamivudine
Number of subjects: 620
Study 14668455 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine and lamivudine combined with efavirenz
Number of subjects: 620
Study 14668455 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial use of zidovudine, lamivudine, and efavirenz
Number of subjects: 620
Study 10710885 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraglobin (400 mg/kg/d x 5)
Number of subjects: 17
Study 10710885 — intervention group
Group type: EXPERIMENTAL
Intervention: Venoglobulin-I (1 g/kg/d x 2)
Number of subjects: 17
Study 10710885 — intervention group
Group type: COMPARATOR
Intervention: Venoglobulin-I
Number of subjects: 17
Study 8726950 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled glucocorticosteroids (standard pediatric doses)
Number of subjects: 0
Study 8726950 — intervention group
Group type: COMPARATOR
Intervention: Inhaled glucocorticosteroids
Number of subjects: 0
Study 1340901 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous Continuous Preprogrammed Insulin Infusion (SCII)
Number of subjects: 28
Study 1340901 — intervention group
Group type: COMPARATOR
Intervention: Multiple Conventional Insulin Injections (MCII)
Number of subjects: 28
Study 1340901 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SCII and MCII
Number of subjects: 28
Study 6502211 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (2 mg, i.v.)
Number of subjects: 0
Study 6502211 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3959854 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 10
Study 3959854 — intervention group
Group type: COMPARATOR
Intervention: CaCO3
Number of subjects: 10
Study 29890270 — intervention group
Group type: EXPERIMENTAL
Intervention: MCC (60 mL·d‐1)
Number of subjects: 16
Study 29890270 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo)
Number of subjects: 16
Study 27401352 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevel-down group
Number of subjects: 204
Study 27401352 — intervention group
Group type: COMPARATOR
Intervention: Bevel-up group
Number of subjects: 204
Study 25333925 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactory ensheathing cells (OECs) intraspinal transplantation
Number of subjects: 28
Study 25333925 — intervention group
Group type: EXPERIMENTAL
Intervention: Schwann cells (SCs) implantation
Number of subjects: 28
Study 25333925 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of OECs and SCs
Number of subjects: 28
Study 25333925 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 28
Study 23341314 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing the video game Dr. Kawashima's Brain Training: How Old Is Your Brain?
Number of subjects: 32
Study 23341314 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not play the video game)
Number of subjects: 32
Study 19889796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (200 mg b.i.d.)
Number of subjects: 20
Study 19889796 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (400 mg once a day)
Number of subjects: 20
Study 18074365 — intervention group
Group type: EXPERIMENTAL
Intervention: AV cued task-specific training
Number of subjects: 52
Study 18074365 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise (Ex)
Number of subjects: 52
Study 16437366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative peritoneal hyperthermic chemotherapy (IPHC)
Number of subjects: 118
Study 16437366 — intervention group
Group type: COMPARATOR
Intervention: Control (no IPHC)
Number of subjects: 118
Study 12839854 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy
Number of subjects: 250
Study 10384736 — intervention group
Group type: EXPERIMENTAL
Intervention: Understanding of materials requiring attribution of mental states (e.g. ignorance, false belief)
Number of subjects: 0
Study 10384736 — intervention group
Group type: COMPARATOR
Intervention: Healthy elderly subjects and a small group of left hemisphere patients (who received the tasks in modified form)
Number of subjects: 0
Study 8887137 — intervention group
Group type: EXPERIMENTAL
Intervention: GH/hMG/hCG
Number of subjects: 42
Study 8887137 — intervention group
Group type: COMPARATOR
Intervention: hMG/hCG
Number of subjects: 42
Study 1648488 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg molsidomine
Number of subjects: 11
Study 1648488 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg isosorbide-5-mononitrate (ISMN)
Number of subjects: 11
Study 1648488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6583715 — intervention group
Group type: EXPERIMENTAL
Intervention: Des-Tyr-gamma-endorphin (DT gamma E) 1 mg, i.m., for 8 consecutive days
Number of subjects: 9
Study 6583715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30584682 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate provisionalization with a non-occluding temporary crown (test group, n = 7)
Number of subjects: 16
Study 30584682 — intervention group
Group type: COMPARATOR
Intervention: Control group (left without a crown, n = 9)
Number of subjects: 16
Study 30584682 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study 29801519 — intervention group
Group type: EXPERIMENTAL
Intervention: VeinViewer®
Number of subjects: 115
Study 29801519 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 115
Study 27703328 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg intrathecal pethidine (P5 group)
Number of subjects: 150
Study 27703328 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg intrathecal pethidine (P10 group)
Number of subjects: 150
Study 27703328 — intervention group
Group type: COMPARATOR
Intervention: Standard group (S group) with 0.5 mL of 0.9% saline
Number of subjects: 150
Study 27703328 — intervention group
Group type: COMPARATOR
Intervention: Standard group (S group)
Number of subjects: 150
Study 25374024 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoids supplementation
Number of subjects: 100
Study 25374024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21814149 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised aerobic exercise (SUP)
Number of subjects: 122
Study 21814149 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 122
Study 20412091 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading group
Number of subjects: 50
Study 20412091 — intervention group
Group type: COMPARATOR
Intervention: Immediate restoration group
Number of subjects: 50
Study 20412091 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study 18632147 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg intravenously at 28-day intervals for 6 months)
Number of subjects: 190
Study 18632147 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 mg/kg at 28-day intervals for 6 months)
Number of subjects: 190
Study 18632147 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 190
Study 18632147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 15924546 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics given prior to delivery
Number of subjects: 0
Study 15924546 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 0
Study 11527656 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin and trace-element supplementation
Number of subjects: 96
Study 11527656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 9722224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation and heat-exchange (MVHE) units
Number of subjects: 10
Study 8035577 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Alcohol Misuse Prevention Study (AMPS) curriculum emphasizing social pressure resistance training, peer support, and norm-setting.
Number of subjects: 0
Study 8035577 — intervention group
Group type: COMPARATOR
Intervention: Control group (curriculum not specified).
Number of subjects: 0
Study 2499342 — intervention group
Group type: EXPERIMENTAL
Intervention: GTN spray (Nitro‐Corangin Spray)
Number of subjects: 12
Study 2499342 — intervention group
Group type: COMPARATOR
Intervention: Another GTN Spray
Number of subjects: 12
Study 977927 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hour training program
Number of subjects: 322
Study 977927 — intervention group
Group type: COMPARATOR
Intervention: Control group (received training after research program)
Number of subjects: 322
Study 30817019 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater AUD severity
Number of subjects: 100
Study 30817019 — intervention group
Group type: COMPARATOR
Intervention: All participants
Number of subjects: 100
Study 28007678 — intervention group
Group type: EXPERIMENTAL
Intervention: ERA+probiotic (Bifidobacterium animalis subsp. lactis B94, 1 capsule/day)
Number of subjects: 159
Study 28007678 — intervention group
Group type: COMPARATOR
Intervention: ERA+placebo (1 capsule/day)
Number of subjects: 159
Study 28007678 — intervention group
Group type: COMPARATOR
Intervention: ERA-only (no additional treatments)
Number of subjects: 159
Study 28007678 — intervention group
Group type: COMPARATOR
Intervention: Combined ERA (ERA+placebo and ERA-only)
Number of subjects: 159
Study 26844861 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200 mg/d)
Number of subjects: 23
Study 26844861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 24222009 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal discussion with handout
Number of subjects: 50
Study 24222009 — intervention group
Group type: COMPARATOR
Intervention: Verbal discussion alone
Number of subjects: 50
Study 23121787 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week commercial weight loss program
Number of subjects: 111
Study 19474651 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r) 300 mg and ritonavir 100 mg daily for 6 months
Number of subjects: 15
Study 19474651 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 15